Development

The following charts summarize the dramatic improvement in hemostasis seen to date in animal testing.

chart-avg-time-hemostasis-control-substance.jpg

The chart above shows the improvement of AC5 Surgical Hemostatic Device™ over both a control substance and a control peptide.

chart-avg-time-hemostasis-cautery-saline.jpg

The last chart shows the improvement of AC5 Surgical Hemostatic Device™ over both cautery and saline control substances.

 

chart-avg-time-hemostasis-brain-tissue.jpg

This chart shows how quickly AC5TM stops bleeding in preclinical studies. The barely discernable green bars illustrate the time required for AC5 to achieve hemostasis (bleeding stopped) compared to the control times in red.


Sources:

  • Ellis-Behnke RG, Liang YX, Tay DKC, Kau PWF, Schneider GE, Zhang S, Wu W and So KF. (2006) Nano hemostat solution: immediate hemostasis at the nanoscale. Nanomedicine 2: 207-15.
    • Comments in Science, JAMA, Nature Biotechnology, Nature nanomedicine, etc.
  • Ellis-Behnke RG. (2011) At the nanoscale: nanohemostat, a new class of hemostatic agent. Wiley Interdiscip Rev Nanomed Nanobiotechnol. 3: 70-8.